ArticleEuropean journal of immunology2026
B-Cell Differentiation of Human Hematopoietic Progenitors Is Efficiently Supported by Wharton Jelly-Derived Mesenchymal Stem Cells.
Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSC) represent the main stromal component of the bone marrow (BM) niche and are crucial to maintain hematopoietic tissue homeostasis. MSC exhibits extraordinary and multiple properties. In terms of expanding potential and differentiation capacity, Wharton jelly MSC (WJ-MSC), derived from the umbilical cord, was described as being greater and more performing than MSC from BM or other sources. WJ-MSC mimics the hematopoietic niche and supports hematopoietic stem cells (HSC) expansion ex vivo. This study aimed to evaluate the effects of human WJ-MSC cocultured with HSC in a B-cell differentiation protocol. Remarkably, results highlight WJ-MSC use as a preferable feeder layer to efficiently support HSC commitment toward the B-lineage. Over 11 days of HSC coculture with WJ-MSC, B-cell genes (E2A, RAG1, RAG2, etc.) expression patterns and B-cell markers (CD19, immunoglobulin chain, etc.) acquisition were evidenced. WJ-MSc were also able to unlock the B-lineage differentiation blockade of the acute lymphoblastic leukemia cell line Nalm16. This model might provide a new strategy to support ex vivo B-cell differentiation using the powerful properties of WJ-MSC. This study implements a new approach to improve understanding of B-leukemogenesis and B-cell acute lymphoblastic leukemia (B-ALL) pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.